Ischemic time as a predictor of physical recovery in the first months after heart transplantation.
Autors de IIS La Fe
Abstract
Functional results after heart transplantation range from modest to spectacular improvement. Little is known about factors to predict functional result. This study aimed to identify these factors. We present a prospective study including all consecutive transplant recipients (n = 55) in a two-year period whose survival was greater than two months. Perioperative, donor, and recipient issues were systematically analyzed. Exercise capacity was assessed by symptom-limited treadmill exercise testing two months after transplantation. Exercise capacity was classified as satisfactory or poor depending on achieving or not 4.5 METs (metabolic equivalents), respectively. Thirty-three patients (60%) showed a good exercise capacity (>4.5 METs), whereas the remaining twenty-two patients (40%) were unable to exceed this threshold. The variables which correlated with exercise capacity in univariate analysis were recipient age, inotropic treatment, ischemic time, ventricular assist device, etiology, urgent transplant, and INTERMACS score. Among them only recipient age and ischemic time were proved to be correlated with exercise capacity in the multiple regression analysis. Thus, younger patients and those who had received an organ with shorter ischemic time showed greater exercise capacity after transplant. These findings strengthen the trend toward reducing ischemic time as much as possible to improve both survival and clinical recovery.
Dades de la publicació
- ISSN/ISSNe:
- 2090-5580, 2090-5599
- Tipus:
- Article
- Pàgines:
- 907102-907102
- DOI:
- 10.5402/2012/907102
- PubMed:
- 22778997
ISRN cardiology
Documents
- No hi ha documents
Filiacions
Projectes associats
REDINSCOR
RD06/0003/1001 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2008
PROYECTO CAIBER
CAI08/01/0061 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009
RED DE BIOBANCOS (BIOBANCOS)
RD09/0076/00021 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010
APOPTOSIS EN EL RECHAZO AGUDO DEL INJERTO CARDIACO ALOGENICO
Investigador Principal: LUIS ALMENAR BONET
AP-196/10 . 2010
CINETICA DEL TRANSPORTE NUCLEO-CITOPLASMATICO DE LOS CARDIOMIOCITOS HUMANOS EN LA INSUFICIENCIA CARDIACA. ANALISIS CELULAR Y DE EXPRESION GENICA
PI10/00275 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010
REGISTRO DE PACIENTES CON INSUFICIENCIA CARDIACA AGUDA
Investigador Principal: LUIS ALMENAR BONET
CP-10 . 2011
ENSAYO CLINICO, MULTINACIONAL, MULTICENTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR LOS EFECTOS HEMODINAMICOS DE RIOCIGUAT (BAY 63-2521), ASI COMO LA SEGURIDAD Y LA FARMACOCINETICA EN PACIENTES CON HIPERTENSION PULMONAR ASOCIADA A UNA DISFUNCION SISTOLICA DEL VENTRICULO IZQUIERDO. ESTUDIO LEPHT.
Investigador Principal: LUIS ALMENAR BONET
BAY63-2521/14308 . 2010
MORE-CRT: EL AUMENTO DE LAS OPCIONES DISPONIBLES CON UN ELECTRODO VI TETRAPOLAR OFRECE SOLUCIONES CLÍNICAS A LOS PROBLEMAS DE LA TRC. MORE OPTIONS AVAILABLE WITH A QUADRIPOLAR LV LEAD PROVIDE IN CLINIC SOLUTIONS TO CRT CHALLENGES.
Investigador Principal: JOAQUÍN OSCA ASENSI
CR-11-006-HF-ID . 2012
ESTUDIO OASIS-H. ORGANIZACION ASISTENCIAL DE PACIENTES CON HOME MONITORING.
Investigador Principal: MARÍA JOSÉ SANCHO-TELLO DE CARRANZA
OASIS-HM . 2010
EVALUACION CLINICA DEL PARADYM RF, NUEVA GAMA DE DAI DE SORIN GROUP.
Investigador Principal: MARÍA JOSÉ SANCHO-TELLO DE CARRANZA
ITSY03 . 2010
ESTUDIO EPICOR: SEGUIMIENTO A LARGO PLAZO DE LAS PAUTAS DE MANEJO ANTITROMBOTICO EN PACIENTES CON SINDROME CORONARIO AGUDO.
Investigador Principal: ANTONIO SALVADOR SANZ
NIS-CEU-DUM-2009/1 . 2011
MONITORING RESYNCHRONIZATION IN CARDIAC PATIENTS.
Investigador Principal: JOSE OLAGUE DE ROS
MORE-CARESTUDY . 2009
ESTUDIO MULTICENTRICO, DOBLE CIEGO Y ALEATORIZADO PARA ESTABLECER LA SEGURIDAD Y LOS EFECTOS CLINICOS BENEFICIOSOS DE VYTORIN (EZETIMIBA/SIMVASTATINA) FRENTE A SIMVASTATINA EN MONOTERAPIA EN PACIENTES DE ALTO RIESGO QUE PRESENTAN SINDROME CORONARIO AGUDO.
Investigador Principal: ANTONIO FLORES PEDAUYE
P04103 . 2007